ProfileGDS5678 / 1423264_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 85% 83% 82% 84% 85% 84% 84% 82% 84% 85% 84% 86% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3769285
GSM967853U87-EV human glioblastoma xenograft - Control 26.4122785
GSM967854U87-EV human glioblastoma xenograft - Control 36.0606983
GSM967855U87-EV human glioblastoma xenograft - Control 46.1388982
GSM967856U87-EV human glioblastoma xenograft - Control 56.2372584
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1988585
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0154484
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1956584
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9157782
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2918384
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.39285
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2834984
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4855686
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3105485